Vaccines against diseases transmitted from animals to humans: A one health paradigm

Vaccine

Volumn 31, Issue 46, 2013, Pages 5321-5338

  Monath, Thomas P ^a,b  

^a One Health Initiative Pro Bono Team ^*

^b PaxVax Inc   (United States)

Author keywords

One Health; Vaccines; Zoonotic diseases

Indexed keywords

EQUIVAC; LYME DISEASE VACCINE; RABIES VACCINE; UNCLASSIFIED DRUG; V 3526; VACCINE;

ANIMAL HEALTH; BRUCELLOSIS; CAT SCRATCH DISEASE; DISEASE CARRIER; DISEASE TRANSMISSION; DOMESTIC ANIMAL; ECONOMIC ASPECT; ESCHERICHIA COLI O157; HENDRA VIRUS; HENDRA VIRUS INFECTION; HUMAN; IMMUNIZATION; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; Q FEVER; RABIES; REVIEW; RIFT VALLEY FEVER; VENEZUELAN EQUINE ENCEPHALITIS; ZOONOSIS;

ONE HEALTH; VACCINES; ZOONOTIC DISEASES;

ANIMALS; ANIMALS, DOMESTIC; ANIMALS, WILD; COMMUNICABLE DISEASES; DISEASE TRANSMISSION, INFECTIOUS; HUMANS; VACCINES; ZOONOSES;

EID: 84886096197     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.029     Document Type: Review

References (203)

1. Kahn L.H., Kaplan B., Monath T.P. The convergence of human and animal medicine. Human-animal medicine. Clinical approaches to zoonoses, toxicants, and other shared risks 2010, 1-6. Saunders Elsevier, Maryland Heights, MO. P.M. Rabinowitz, L.A. Conti (Eds.).
2. Woolhouse M.E., Gowtage-Sequeria S. Host range and emerging and reemerging pathogens. Emerg Infect Dis 2005, 11:1842-1847.
3. Greger M. The human/animal interface: emergence and resurgence of zoonotic infectious diseases. Crit Rev Microbiol 2007, 33:243-299.
4. One Health-One Medicine: linking human, animal, and environmental health. Vet Ital 2009, 45(January-March (1)). 215 pp.
5. People, pathogens and our planet: vol. 2. The economics of One Health 2012, 1-50. World Bank, [Rep No. 69145-GLB].
6. Lurie N., Manolio T., Paterson A.P., Collins F., Frieden T. Research as a part of public health emergency response. N Engl J Med 2013, 368:1251-1255.
7. Grace D., Gilbert J., Randolph T., Kang'ethe E. The multiple burdens of zoonotic disease and an Ecohealth approach to their assessment. Trop Anim Health Prod 2012, 44(Suppl. 1):S67-S73.
8. AVMA One Health: A New Professional Imperative: AVMA One Health Initiative Task Force Report 2008, Available from:. https://www.avma.org/KB/Resources/Reports/Documents/onehealth_final.pdf.
9. Aebersold P. FDA experience with medical countermeasures under the animal rule. Adv Prev Med 2012, 11 pp. [Article ID 507571].
10. Calistri P., Giovannini A., Hubalek Z., et al. Epidemiology of West Nile in Europe and in the Mediterranean Basin. Open Virol J 2010, 4:29-37.
11. MurrayKO, Mertens E., Despres P. West Nile virus and its emergence in the United States of America. Vet Res 2010, 41:67.
12. Lindsey N.P., Kuhn S., Campbell G.L., Hayes E.B. West Nile virus neuroinvasive disease incidence in the United States, 2002-2006. Vector Borne Zoonotic Dis 2008, 8:35-40.
13. Hayes E.B., Gubler D. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med 2006, 57:181-194.
14. Centers for Disease Control, Atlanta, GA. http://www.cdc.gov/westnile/resources/pdfs/cummulative/99_2012_cummulativeHumanCases.pdf.
15. Centers for Disease Control, Atlanta, GA. http://www.cdc.gov/westnile/resources/pdfs/cummulative/99_2012_NeuroInvasive%20byYear.pdf.
16. Labowitz Klee A., Maldin B., Edwin E., et al. Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis 2004, 10:1405-1411.
17. US Department of Agriculture.
18. Epp T., Waldner C., Townsend H.G. A case-control study of factors associated with development of clinical disease due to West Nile virus, Saskatchewan 2003. Equine Vet J 2007, 39:498-503.
19. Guirakhoo F., Zhang Z., Chambers T.J., et al. Immunogenicity, genetic stability and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (Chimerivax™-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 1999, 257:363-372.
20. Monath T.P., Soike K., Levenbook I., et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 1999, 17:1869-1882.
21. Arroyo J., Miller C.A., Catalan J., Monath T.P. Yellow fever vector live-virus vaccines: West Nile vaccine development. Trends Mol Med 2001, 7:329-377.
22. Arroyo J., Miller C., Catalan J., et al. ChimeriVax™-West Nile live-attenuated vaccine: preclinical evaluation of safety, immunogenicity and efficacy. J Virol 2004, 78:12497-12507.
23. Monath T.P., Arroyo J., Miller C., Guirakhoo F. West Nile vaccine. Curr Drugs Infect Dis 2001, 1:37-50.
24. Bowen R.A., Gordy P., Mellencamp M.W., Baker D. Efficacy of a live attenuated chimeric West Nile virus vaccine in horses against clinical disease following challenge with virulent West Nile virus, abstr. 2096. Suppl. proc. 53rd annu. meet. Am. J. Trop. Med. Hyg. 2004.
25. Seino K.K., Long M.T., Gibbs E.P.J., et al. Comparative efficacies of three commercially available vaccines against West Nile (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model. Clin Vaccine Immunol 2007, 14:1465-1471.
26. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., et al. A live, attenuated recombinant vaccine against West Nile virus. Proc Natl Acad Sci USA 2006, 103:6694-6699.
27. http://www.equinechronicle.com/health/ask-the-vet/vaccination-update.html.
28. Yeh J.-Y., Chung K.M., Song J. Differentiation of West Nile virus-infected animals from vaccinated animals by competitive ELISA using monoclonal antibodies against non-structural protein 1. Vector Borne Zoonotic Dis 2012, 12:380-387.
29. Corbel M. Brucellosis: an overview. Emerg Infect Dis 1997, 3:213-221.
30. Pappas G., Papadimitriou P., Akritidis N., et al. The new global map of human brucellosis. Lancet Infect Dis 2006, 6:91-99.
31. Perkins S.D., Smither S.J., Atkins H.S. Towards a Brucella vaccine for humans. FEMS Microbiol Rev 2010, 34:379-394.
32. Dean A.S., Crump L., Greter H., et al. Clinical manifestations of human Brucellosis: a systematic review and meta-analysis. PLoS Negl Trop Dis 2012, 6(12):e1929.
33. Roth F., Zinsstag J., Orkhon D., et al. Human health benefits from livestock vaccination for brucellosis: case study. Bull WHO 2003, 81:867-876.
34. Flicht T.A., Kahl-McDonagh M.M., Arenas-Gamboa A.M., et al. Brucellosis: The Case for Live, Attenuated Vaccines. Vaccine 2009, 27(Suppl. 4):D40-D43.
35. Moriyon I., Grillo M.J., Monreal D., et al. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res 2004, 35:1-38.
36. Ebel E.D., Williams M.S., Tomlinson S.M. Estimating herd prevalence of bovine brucellosis in 46 US states using slaughter surveillance. Prev Vet Med 2008, 85:295-326.
37. Treanor J.J., Johnson J.S., Wallen R.L., et al. Vaccination strategies for managing brucellosis in Yellowstone basin. Vaccine 2010, 28(Suppl. 5):F64-F72.
38. Yang Y., Skyberg J.A., Cao L., et al. Progress in Brucella vaccine development. Front Biol (Beijing) 2013, 8:60-77.
39. Jelastopulu E., Bikas C., Petropoulos C., Leotsinidis M. Incidence of human brucellosis in a rural area in Western Greece after the implementation of a vaccination programme against animal brucellosis. BMC Public Health 2008, 8:241-245.
40. Gupta K.V., Radhakrishnan, Harms J., Splitter G. Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis. Vaccine 2012, 30:4017-4022.
41. Hu X.D., Yu D.H., Chen S.T., et al. A combined DNA vaccine provides protective immunity against Mycobacterium bovis and Brucella abortus in cattle. DNA Cell Biol 2009, 28:191-199.
42. Olsen S.C., Jensen A.E., Stoffregen W.C., Palmer M.V. Efficacy of calfhood vaccination with Brucella abortus strain RB51 in protecting bison against brucellosis. Res Vet Sci 2003, 74:17-22.
43. Voetsch A.C., Kennedy M.H., Keene W.E., et al. Risk factors for sporadic Shiga toxin-producing Escherichia coli O157 infections in FoodNet sites, 1999-2000. Epidemiol Infect 2007, 135:993-1000.
44. Arthur T.M., Bosilevac J.M., Nou X., et al. Escherichia coli O157 prevalence and enumeration of aerobic bacteria, Enterobacteriaceae, and Escherichia coli O157 at various steps in commercial beef processing plants. J Food Prot 2004, 67:658-665.
45. Jacob M.E., Renter D.G., Nagaraja T.G. Animal- and truckload-level associations between Escherichia coli O157:H7 in feces and on hides at harvest and contamination of preevisceration beef carcasses. J Food Prot 2010, 73:1030-1037.
46. ® Escherichia coli O157 bacterial extract vaccine. Product Monograph 2012, http://www.econichevaccine.com/.
47. Thomson D.U., Loneragan G.H., Thornton A.B., et al. Use of a siderophore receptor and porin proteins-based vaccine to control the burden of Escherichia coli O157:H7 in feedlot cattle. Foodborne Pathog Dis 2009, 6:871-877.
48. Thornton A.B., Thomson D.U., Loneragan G.H., et al. Effects of a siderophore receptor and porin proteins-based vaccination on fecal shedding of Esherichia coli O157:H7 in experimentally inoculated cattle. J Food Prot 2009, 72:866-869.
49. Hurd H.S., Malladi S. An outcomes model to evaluate risks and benefits of Escherichia coli vaccination in beef cattle. Foodborne Pathog Dis 2012, 9:952-961.
50. Chomel B.B., Boulois H.-J., Maruyama S., Breitschwerdt E.B. Bartonella spp. in pets and effect on human health. Emerg Infect Dis 2006, 12:389-394.
51. Day M.J. One health: the importance of companion animal vector-borne diseases. Parasites Vectors 2011, 4:49.
52. Birtles R. Bartonellosis. Arthropod-borne infectious diseases of the dog and cat 2005, 110-119. Manson Publishing Ltd, London. S.E. Shaw, M.J. Day (Eds.).
53. Meslin F.X., Miles M.A., Vexenat A., Gemmell M.A. Zoonoses Control in dogs. Dogs, zoonoses and public health 2000, 333-372. CABI Publishing, Wallingford, UK. C.N.L. MacPherson, F.X. Meslin, A.I. Wandeler (Eds.).
54. Clifton M. How to eradicate canine rabies: a perspective of historical efforts. Asian Biomed 2011, 5:559-568.
55. Chomel B., Chappuis G., Bullon F., et al. Mass vaccination campaign against rabies: are dogs correctly protected? The Peruvian experience. Rev Infect Dis 1988, Suppl. 4:S697-S702.
56. Hemachudha T., Laothamatas J., Rupprecht C.E. Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges. Lancet Neurol 2002, 1:101-109.
57. Knobel D.L., Cleaveland S., Coleman P.G., et al. Re-evaluating the burden of rabies in Africa and Asia. Bull WHO 2005, 83:360-368.
58. Frost & Sullivan Global Vaccine Market Report 2009, 84 pp.
59. Ben Youssef S., Matter H.C., Schumacher C.L., et al. Field evaluation of a dog owner, participation-based, bait delivery system for the oral immunization of dogs against rabies in Tunesia. Am J Trop Med Hyg 1998, 58:835-845.
60. World Health Organization Field application of oral rabies vaccines for dogs 1998, World Health Organization, Geneva.
61. Estrada R., Vos A., De Leon R., Mueller T. Field trial with oral vaccination of dogs against rabies in the Philippines. BMC Infect Dis 2001, 1:23.
62. Vos A., Müller T., Schuster P., Schlüter H., Neubert A. Oral vaccination of foxes against rabies with SAD B19 in Europe, 1983-1998: a review. Vet Bull 2000, 70:1-5.
63. Rupprecht C.E., Hanlon C.A., Blanton J., Manangan J., Morrill P., Murphy S., et al. Oral vaccination of dogs with recombinant rabies virus vaccines. Virus Res 2005, 111:101-105.
64. Crawford B., Roth I., Grillo T. One Health and Hendra virus: a collaborative approach in action. New South Wales Public Health Bull 2012, 23:160.
65. Eaton B.T., Broder C.C., Middleton D., Wang L.-F. Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol 2006, 4:23-35.
66. Halpin K., Hyatt A.D., Fogarty R., et al. Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission. Am J Trop Med Hyg 2011, 85:946-951.
67. Field H.E., Mackenzie J.S., Daszak P. Henipaviruses: emerging paramyxoviruses associated with fruit bats. Curr Top Microbiol Immunol 2007, 315:133-159.
68. CSIRO, Australia. http://www.csiro.au/en/Outcomes/Food-and-Agriculture/Hendra-Virus.aspx.
69. Williamson M.M., Torres-Velez F.J. Henipavirus: a review of laboratory animal pathology. Vet Pathol 2010, 47:871-880.
70. Balzer M. Hendra vaccine success announced. Aust Vet J 2011, 89:N2-N3.
71. Mendez D.H., Judd J., Speare R. Unexpected result of Hendra virus outbreaks for veterinarians, Queensland, Australia. Emerg Infect Dis 2012, 18:83-85.
72. Bossart K.N., Crameri G., Dimitrov A.S., et al. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol 2005, 79:6690-6702.
73. Pallister J., Middleton D., Wang L.-F., et al. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine 2011, 29:5623-5630.
74. Bossart K.N., Rockx, Feldmann F., et al. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med 2012, 4. 146146ra107. 10.1126/scitranslmed.3004241.
75. http://www.horseoz.com/adelaide/Horse_Industry_Events_Sponsors/horse_industry_events_sponsors.html.
76. Swanepoel R., Coetzer J.A.W. Rift Valley fever. Infectious diseases of livestock 1994, Oxford University Press, Capetown. J.A.W. Coetzer, G.R. Thomson, R.D. Tustin (Eds.).
77. Kahlon S.S., Peters C.J., Leduc J., et al. Severe Rift Valley fever may present with a characteristic clinical syndrome. Am J Trop Med Hyg 2010, 82:371-375.
78. Madani T.A., Al-Mazrou Y.Y., Al-Jeffri M.H., et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 2003, 37:1084-1092.
79. Pepin M., Bouloy M., Bird B.H., et al. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 2010, 41:61.
80. Linthicum K.J., Davies F.G., Kairo A., Bailey C.L. Rift Valley fever virus (family Bunyaviridae, genus Phlebovirus). Isolations from Diptera collected during an inter-epizootic period in Kenya. J Hyg (Lond) 1985, 95:197-209.
81. Anyamba A., Chretien J.P., Small J., et al. Prediction of a Rift Valley fever outbreak. Proc Natl Acad Sci USA 2009, 106:955-959.
82. Bird B.H., Nichol S.T. Breaking the chain: Rift Valley fever virus control via livestock vaccination. Curr Opin Virol 2012, 2:315-323.
83. Smithburn K.C. Rift Valley fever: the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol 1949, 30:1-16.
84. Botros B., Omar A., Elian K., et al. Adverse response of nonindigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol 2006, 78:787-791.
85. Barnard B.J., Botha M.J. An inactivated Rift Valley fever vaccine. J S Afr Vet Assoc 1977, 48:45-48.
86. World Health Organization The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from a WHO/FAO meeting. Bull WHO 1983, 61:261-268.
87. Atwa M.H., El-Sabagh M., Amer H.M., et al. ZH501-VSVRI: Is it still the best choice for vaccination against Rift Valley fever in Egypt?. J Vaccines Vaccin 2011, 2:3.
88. Pittman P.R., Liu C.T., Cannon T.L., et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 2000, 18:181-189.
89. Niklasson B.S., Meadors G.F., Peters C.J. Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters. Acta Pathol Microbiol Immunol Scand 1984, 92:197-200.
90. Caplen H., Peters C.J., Bishop D.H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 1985, 66:2271-2277.
91. Saluzzo J.F., Smith J.F. Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine 1990, 8:369-375.
92. Vialat P., Muller R., Vu T.H., et al. Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation. Virus Res 1997, 52:43-50.
93. Peters C.J. Emergence of Rift Valley fever. Factors in the emergence of arbovirus diseases 1997, 253-264. Elsevier, Paris. J.F. Saluzzo, B. Dodet (Eds.).
94. Morrill J.C., Mebus C.A., Peters C.J. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 1997, 58:1104-1109.
95. Morrill J.C., Jennings G.B., Caplen H., et al. Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am J Vet Res 1987, 48:1042-1047.
96. Hunter P., Erasmus B.J., Vorster J.H. Teratogenicity of a mutagenised Rift Valley fever virus (MVP12) in sheep. Onderstepoort J Vet Res 2002, 69:95-98.
97. Ikegami T., Won S., Peters C.J., Makino S. Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking NSs gene, and expression of a foreign gene. J Virol 2006, 80:2933-2940.
98. Bird B.H., Albarino C.G., Hartman A.L., et al. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 2008, 82:2681-2691.
99. Morrill J.C., Laughlin R.C., Lokugamage N., et al. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Vaccine 2013, 31:559-565.
100. Muller R., Saluzzo J.F., Lopez N., et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 1995, 53:405-411.
101. Swanepoel R., Coetzer J.A.W. Rift Valley fever. Infectious diseases of livestock 2004, 1037-1070. Oxford University Press, Cape Town, South Africa. 2nd ed. J.A.W. Coetzer, R.D. Tustin (Eds.).
102. Dungu B., et al. Evaluation of the efficacy and safety of the Rift Valley fever clone 13 vaccine in sheep. Vaccine 2010, 28:4581-4587.
103. Wallace D.B., Ellis C.E., Espach A., et al. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 2006, 24:7181-7189.
104. Heise M.T., Whitmore A., Thompson J., et al. An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus. Epidemiol Infect 2009, 137:1-10.
105. Kortekaas J., de Boer S.M., Kant J., Vloet, et al. Rift Valley fever virus immunity pro-vided by a paramyxovirus vaccine vector. Vaccine 2010, 28:4394-4401.
106. Indran S.V., Ikegami T. Novel approaches to develop Rift Valley fever vaccines. Front Cell Infect Microbiol 2012, 10.3389/fcimb 2012.00131.
107. Boshra H., Lorenzo G., Busquets N., Brun A. Rift Valley fever: recent insights into pathogenesis and prevention. J Virol 2011, 85:6098-6105.
108. Naslund J., Lagerqvist N., Habjan M., et al. Vaccination with virus like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 2009, 385:409-415.
109. Lorenzo G., Martin-Folgar R., Rodriguez F., Brun A. Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. Vaccine 2008, 26:5255-5262.
110. Aguilar P.V., Estrada-Franco J.G., Navarro-Lopez R., et al. Endemic Venezuelan equine encephalitis in the Americas: Hidden under the dengue umbrella. Future Virol 2011, 6:721-740.
111. Anishchenko M., Bowen R.A., Paessler S., et al. Venezuelan encephalitis emergence mediated by a phylogenetically predicted viral mutation. Proc Natl Acad Sci USA 2006, 103:4994-4999.
112. Groot H. The health and economic impact of Venezuelaqn equine encephalitis (VEE). Venezuelan encephalitis. Proceedings of the workshop - symposium on Venezuelan equine encephalitis 1972, 7-16. Pan Amer Hlth Org, Sci Pub No. 243.
113. McKinney R.W. Inactivated and live VEE vaccines-a review. Venezuelan encephalitis. Proceedings of the workshop - symposium on Venezuelan equine encephalitis 1972, 369-376. Pan Amer Hlth Org, Sci Pub No. 243.
114. Rivas F., Diaz L.A., Cardenas V.M., et al. Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995. J Infect Dis 1997, 175:828-832.
115. Weaver S.C., Salas R., Rico-Hesse R., et al. Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group. Lancet 1996, 348:436-440.
116. Smith J.F., Davis K., Hart M.K., et al. Viral encephalitides. Medical aspects of chemical and biological warfare. Textbook of military medicine, Part I 1997, 561-590. Office of the Surgeon General, Washington, DC. F.R. Sidell, E.W.T. Takafugi, D.R. Franz (Eds.).
117. Berge C.E., Banks T.S., Tiggert W.D. Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea pig heart cells. Am J Hyg 1961, 74:209-218.
118. Pittman P.R., Makuch R.S., Magnafico J.A., et al. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 1996, 14:337-343.
119. Kinney R.M., Chang G.J., Tsuchiya K.R., et al. Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein. J Virol 1993, 67:1269-1277.
120. Gouchenour W.S., Berge T.O., Gleiser C.A., Tiggert W.D. Immunization of burros with living Venezuelan equine encephalitis virus. Am J Hyg 1962, 75:351-362.
121. Spertzel R.C., Kahn D.E. Safety and efficacy of an attenuated VEE vaccine for use in equidae. J Am Vet Med Assoc 1971, 159:731-738.
122. Eddy G.A., Martin D.H., Reeves W.C., Johnson K.M. Field studies of an attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83). Infect Immun 1972, 5:160-163.
123. Paessler S., Weaver S.C. Vaccines for Venezuelan equine encephalitis. Vaccine 2009, 27(Suppl. 4):D80-D85.
124. Pratt W.D., Davis N.L., Johnston R.E., Smith J.F. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 2003, 21:3854-3862.
125. Fine D.L., Roberts B.A., Terpening S.J., et al. Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates. Vaccine 2008, 26:3497-3506.
126. Fine D.L., Roberts B.A., Teehee M.L., et al. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Vaccine 2007, 25:1868-1876.
127. Martin S.S., Bakken R.R., Lind C.M., et al. Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus. Vaccine 2010, 28:3143-3151.
128. Paessler S., Fayzulin R.Z., Anishchenko M., et al. Recombinant Sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic. J Virol 2003, 77:9278-9286.
129. Mencher J.S., Smith S.R., Powell T.D., et al. Protection of black-tailed prairie dogs (Cynomys ludovicianus) against plague after voluntary consumption of baits containing recombinant raccoon poxvirus vaccine. Infect Immun 2004, 72:5502-5505.
130. Olsen S.C., Kreeger T.J., Schultz W. Immune responses of bison to ballistic or hand vaccination with Brucella abortus strain RB51. J Wildl Dis 2002, 38:738-745.
131. Creekmore T.E., Rocke T.E., Hurley J. A baiting system for delivery of an oral plague vaccine to black-tailed prairie dogs. J Wildl Dis 2002, 38:32-39.
132. Embers M.E., Narasimhan S. Vaccination against Lyme disease. Front Cell Infect Microbiol 2013, 6. 10.3389/foimb.2013.00006.
133. Radolf J.D., Caimano M.J., Stevenson B., Hu L.T. Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat Rev Microbiol 2012, 10:87-99.
134. Steere A.C., Coburn J., Glickstein L. The emergence of Lyme disease. J Clin Invest 2004, 113:1093-1101.
135. Poland G.A. Vaccines against Lyme disease: what happened and what lessons can we learn?. Clin Infect Dis 2011, 52(Suppl. 3):S253-S258.
136. Meltzer M.I., Dennis D.T., Orloski K.A. The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis 1999, 5:321-328.
137. Ma J., Hine P.M., Clough E.R., et al. Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine. Vaccine 1996, 14:1366-1374.
138. Poland G.A. Prevention of Lyme disease: a review of the evidence. Mayo Clin Proc 2002, 76:713-724.
139. Plotkin S.A. Correcting a public health fiasco: the need for a new vaccine against Lyme disease. Clin Infect Dis 2011, 52(Suppl. 3):S271-S275.
140. Fikrig E., Telford S.R., Barthold S.W., et al. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA immunized mice. Proc Natl Acad Sci U S A 1992, 89:5418-5421.
141. de Silva A.M., Telford S.R., Brunet L.R., et al. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J Exp Med 1996, 183:271-275.
142. Tsao J.I., Wootton J.T., Bunikis J., et al. An ecological approach to preventing human infection: vaccinating wild mouse reservoirs intervenes in the Lyme disease cycle. Proc Natl Acad Sci USA 2004, 101:18159-18164.
143. Gomes-Solecki M.J.C., Brisson D.R., Dattwyler R.J. Oral vaccine that breaks the transmission cycle of the Lyme disease spirochete can be delivered via bait. Vaccine 2006, 24:4440-4449.
144. Richer L.M., Aroso M., Contente-Cuomo T., et al. Reservoir targeted vaccine for Lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice. Clin Vaccine Immunol 2011, 18:1809-1816.
145. Scheckelhoff M.R., Telford S.R., Hu L.T. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Vaccine 2006, 24:1949-1957.
146. Bhattacharya D., Bensaci M., Luker K.E., et al. Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme disease. Vaccine 2011, 29:7818-7825.
147. de la Rua-Domenech R. Human Mycobacterium bovis infection in the United Kingdom: incidence, risks, control measures and review of the zoonotic aspects of bovine tuberculosis. Tuberculosis 2006, 86:77-109.
148. Majoor C.J., Magis-Escura C., van Ingen J., et al. Epidemiology of Mycobacterium bovis disease in humans, the Netherlands, 1993-2007. Emerg Infect Dis 2011, 17:457-463.
149. Cosivi O., Grange J.M., Daborn C.J., et al. Zoonotic tuberculosis due to Mycobacterium bovis in developing countries. Emerg Infect Dis 1998, 4:59.
150. Humblet M.-F., Boschiroli M.L., Saegerman C. Classification of worldwide bovine tuberculosis risk factors in cattle: a stratified approach. Vet Rec 2009, 40:50-60.
151. Benévolo-de-Andrade T.C., Monteiro-Maia R., Cosgrove C., Castello-Branco L.R.R. BCG Moreau Rio de Janeiro-an oral vaccine against tuberculosis-review. Mem Inst Oswaldo Cruz 2005, 100:459-465.
152. Okator C.C., Grooms D.L., Bruning-Fann C.S., et al. Descriptive epidemiology of bovine tuberculosis in Michigan (1975-2010): lessons learned. Vet Med Int 2011, 2011:874924.
153. Vicente J., Höfle U., Garrido J.M., et al. Risk factors associated with the prevalence of tuberculosis-like lesions in fenced wild boar and red deer in south central Spain. Vet Res 2007, 38:451-464.
154. Smith G.C., McDonald R.A., Wilkinson D. Comparing badger (Meles meles) management strategies for reducing tuberculosis incidence in cattle. PLoS ONE 2012, 7:e39250.
155. De Vos V., Bengis R.G., Kriek N.P.J., et al. The epidemiology of tuberculosis in free-ranging African buffalo (Syncerus caffer) in the Kruger National Park, South Africa. Onderstepoort J Vet Res 2001, 68:119-130.
156. Morris R.S., Pfeiffer D.U. Directions and issues in bovine tuberculosis epidemiology and control in New Zealand. NZ Vet J 1995, 43:256-265.
157. Collins D.M., de Lisle G.W., Aldwell F.E., Buddle B.M. A new attenuated Mycobacterium bovis vaccine protects brushtail possums (Trichosurus vulpecula) against experimental tuberculosis infection. Vaccine 2007, 25:4659-4664.
158. Tompkins D.M., Ramsey D.S.L., Cross M.L., et al. Oral vaccination reduces the incidence of tuberculosis in free-living brushtail possums. Proc Biol Sci B 2009, 276:2987-2995.
159. Cross M.L., Henderson R., Lambeth M.R., et al. Lipid-formulated BCG as an oral-bait vaccine for tuberculosis: vaccine stability, efficacy and palatability to New Zealand possums (Trichosurus vulpecula). J Wildl Dis 2009, 45:754-765.
160. Wandeler A. Epidemiology of fox rabies. Biogeographica 1980, vol. 18:237-250. Dr. W. Junk B.V. Publishers, The Hague. E. Zimen (Ed.).
161. Debbie J.G., Abselseth M.K., Baer G.M. The use of commercially available vaccines for the oral vaccination of foxes against rabies. Am J Epidemiol 1972, 96:231-235.
162. Baer G.M., Abeleth M.K., Debbie J.G. Oral immunization of foxes against rabies. Am J Epidemiol 1971, 95:487-490.
163. Winkler W.G. A review of the development of the oral vaccination technique for immunizing wildlife against rabies. Wildlife rabies control 1992, 82-96. Wells Medical, Royal Turnbridge Wells, UK. K. Bögel, F.X. Meslin, M. Kaplan (Eds.).
164. Steck F., Wandeler A., Bischel P., et al. Oral immunization of foxes against rabies. Laboratory and field studies. Comp Immunol Microbiol Infect Dis 1982, 5:165-171.
165. Thulke H.-H., Selhorst T., Muller T., et al. Assessing anti-rabies baiting-what happens on the ground?. BMC Infect Dis 2004, 4:9.
166. Bugnon P., Breitenmoser U., Peterhans E., Zanoni R. Efficacy of oral vaccination in the final stage of fox rabies elimination in Switzerland. J Vet Med B Infect Dis Vet Public Health 2004, 51:433-437.
167. World Health Organization WHO Expert Consultation on Rabies. WHO Tech Rep Ser 931 2004, 1-121.
168. Linhart S.B., Kappeler A., Windberg L.A. A review of baits and bait delivery systems for free-ranging carnivores and ungulates. Contraception in wildlife management, Paper 17 1993, 69-132. Univ. Nebraska. http://digitalcommons.unl.edu/nwrccontraception/17.
169. Lafay F., Benejean J., Tuffereau C., et al. Vaccination against rabies: construction and characterization of SAG2, a double avirulent derivative of SADBern. Vaccine 1994, 12:317-320.
170. Mackowiak M., Maki J., Motes-Kreimeyer L., et al. Vaccination of wildlife against rabies: successful use of a vectored vaccine obtained by recombinant technology. Adv Vet Med 1999, 41:571-583.
171. Wiktor T.J., MacFarlan R.I., Reagan K.J., et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci USA 1984, 81:7194-7198.
172. Buller R.M.L., Smith G.L., Cremer K., et al. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985, 317:813-815.
173. Baer G.M. The oral rabies immunization of foxes and dogs with sausage baits. Dev Biol Stand 1976, 33:417-423.
174. Artois M., Masson E., Barrat J., Aubert M.F.A. Efficacy of three oral rabies vaccine baits in the red fox: a comparison. Vet Microbiol 1993, 38:167-172.
175. MΦrk T., Prestrud P. Arctic rabies - a review. Acta Vet Scand 2004, 45:1-9.
176. Grosenbaugh D.A., Maki J.L., Rupprecht C.E., Wall D.K. Rabies challenge of captive striped skunks (Mephitis mephitis) following oral administration of a live vaccinia-vectored rabies vaccine. J Wildl Dis 2007, 43:124-128.
177. Slate D., Algeo T.P., Nelson K.M., et al. Oral rabies vaccination in North America: opportunities, complexities, and challenges. PLoS Negl Trop Dis 2009, 3:e549.
178. Blanton J.D., Hanlon C.A., Rupprecht C.E. Rabies surveillance in the United States during 2006. J Am Vet Med Assoc 2007, 231:540-556.
179. Rupprecht C.E., Smith J.S. Raccoon rabies: the re-emergence of an epizootic in a densely populated area. Semin Virol 1994, 5:155-164.
180. Root J.J., McLean R.G., Slate D., et al. Potential effect of prior raccoonpox virus infection in raccoons on vaccinia-based rabies immunization. BMC Immunol 2008, 9:57.
181. Sterner R.T., Meltzer M.I., Shwiff S.A., Slate D. Tactics and economics of wildlife oral rabies vaccination, Canada and the United States. Emerg Infect Dis 2009, 15(August):1176-1184.
182. Kemere P., Liddel M., Evangelou P., et al. Economic analysis of a large scale oral vaccination program to control raccoon rabies. Proc. 3rd NWRC special symposium - human conflicts with wildlife: economic considerations 2002, 109-116. L. Clark, J. Hone, J.A. Shivik (Eds.).
183. Kuzmin I.V., Shi M., Orciani L.A., et al. Molecular inferences suggest multiple host shifts of rabies viruses from bats to mesocarnivores in Arizona during 2001-2009. PLoS Pathog 2012, 8:e1002786.
184. Yarosh O.K., Wandeler A.I., Graham F.L., et al. Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine 1996, 14:1257-1264.
185. Rosatte R.C., Donovan D., Davies J.C., et al. Aerial distribution of ONRAB baits as a tactic to control rabies in raccoons and striped skunks in Ontario, Canada. J Wildl Dis 2009, 45:363-374.
186. ® rabies vaccine baits to control arctic-variant rabies in striped skunks in Ontario, Canada. J Wildl Dis 2011, 47:459-465.
187. Keiser J., Maltese M.F., Erlanger T.E., et al. Effect of irrigated rice agriculture on Japanese encephalitis, including challenges and opportunities for integrated vector management. Acta Trop 2005, 95:40-57.
188. Habu A., Murakami Y., Ogasa A., Fujisaki Y. Disorder of spermatogenesis and viral discharge into semen in boars infected with Japanese encephalitis virus. Virus 1977, 27:21-26.
189. Lindahl J.F., Chirico J., Boqvist S., et al. Occurrence of Japanese encephalitis virus mosquito vectors in relation to urban pig holdings. Am J Trop Med Hyg 2012, 87:1076-1082.
190. Porter S.R., Czaplicki G., Mainil J., et al. Q fever: current state of knowledge and perspectives of research of a neglected zoonosis. Int J Microbiol 2011, 22 pp. [Article ID 248418]. 10.1155/2011/248418.
191. Roest H.I.J., Tilburg J.J.H.C., van der Hoek W., et al. The Q fever epidemic in the Netherlands: history, onset, response and reflection. Epidemiol Infect 2011, 139:1-12.
192. Angelakis E., Raoult D. Q fever. Vet Microbiol 2010, 140:297-309.
193. Guatteo R., Joly A., Rodolakis A., et al. Prévention de l'excrétion de Coxiella burnetii à l'aide d'un vaccin phase I (Coxevac en troupeaux bovines laitiers infectés). Rencontres Recherches Rumin 2008, 15:59-62.
194. Ackland J.R., Worswick D.A., Marmion B.P. Vaccine prophylaxis of Q fever-a follow-up study of the efficacy of Q-Vax (CSL) 1985-1990. Med J Aust 1994, 160:704-708.
195. Ormsbee R.A., Marmion B.P. Prevention of Coxiella bumetii infection: vaccines and guidelines for those at risk. Q fever, vol. I. The disease 1990, 225-248. CRC Press, Boca Raton, FL. T.J. Marrie (Ed.).
196. Astobiza I., Barandika J.F., Ruiz-Fons F., et al. Four-year evaluation of the effect of vaccination against Coxiella burnetii on reduction of animal infection and environmental contamination in a naturally infected dairy sheep flock. Appl Environ Microbiol 2011, 77:7405-7407.
197. Gray G.C., Baker W.S. The importance of including swine and poultry workers in influenza vaccination programs. Clin Pharmacol Ther 2007, 8:638-641.
198. Schelling E., Bechir M., Ahmed A.M., et al. Human and animal vaccination delivery to remote nomadic families, Chad. Emerg Infect Dis 2007, 13:373-379.
199. Rosatte R., Donovan D., Allan M., et al. Emergency response to raccoon rabies introduction into Ontario. J Wildl Dis 2001, 37:265-279.
200. Andre F.E. How the research-based industry approaches vaccine development and establishes priorities. Dev Biol (Basel) 2002, 110:25-29.
201. Meeusen E.N.T., Walker J., Peters A., et al. Current status of veterinary vaccines. Clin Microbiol Rev 2007, 20:489-510.
202. Serdobova I., Kieny M.-P. Assembling a global vaccine development pipeline for infectious diseases in the developing world. Am J Public Health 2006, 96:1554-1559.
203. http://www.galvmed.org/.